Biotechnology

AmyriAD Acquires AD04 Alzheimer’s Program for Phase 2B Development

Louis Mbaye
Add Securities.io to your preferred sources on Google
Key PointsAmyriAD acquired AD04 to add an immune-directed Alzheimer's program alongside its lead…
View more
  • AmyriAD acquired AD04 to add an immune-directed Alzheimer's program alongside its lead candidate Ismidenon.
  • AD04's cognitive and imaging signals came from a control arm rather than a prospective trial.
  • A 2025 post-hoc analysis called the AD04 benefit hypothesis-generating rather than confirmatory.

AmyriAD Therapeutics acquired worldwide rights to ADvantage Therapeutics’ AD04 Alzheimer’s disease program, including associated intellectual property, clinical data and regulatory assets, the company said in a November 16, 2026 announcement. Financial terms were not disclosed.

Amsterdam-based AmyriAD described AD04 as a Phase 2b-ready program targeting neuroinflammation in mild Alzheimer’s disease. It complements Ismidenon, the company’s lead candidate for cognitive impairment in moderate Alzheimer’s disease, extending the portfolio across different biological mechanisms and stages of cognitive decline.

ADvantage CEO Jeffrey B. Madden and members of its clinical and scientific team will continue to support AD04 in advisory roles, providing continuity and program expertise. “Following our acquisition of Recognify Life Sciences, AD04 further expands our cognition pipeline alongside lead program Ismidenon,” said K. Ranga Rama Krishnan, AmyriAD’s chairman and CEO.

Evidence From the Original Control Arm

AD04 is an investigational, subcutaneously administered aluminum hydroxide hydrogel with a specific, proprietary dose. AmyriAD says its proposed mechanism begins with peripheral inflammation and results in inflammation resolution in the brain and the elimination of waste, including lipid microdroplets. The clinical rationale emerged from AFF006, a 332-patient Phase 2 Alzheimer’s vaccine study in which AD04 served as a control treatment.

ADvantage’s program record dates the randomized, double-blind trial to 2014 and describes a 51-patient control arm receiving 2 mg of AD04, with slower decline on cognition and quality-of-life measures and on MRI-measured hippocampal volume than in the four other study groups combined.

ADvantage’s account also describes that arm as safe and well tolerated, with no evidence of autoimmunity, hematological abnormalities, or liver or kidney toxicity. It says reduced hippocampal-volume loss correlated with less decline on the adapted Alzheimer’s Disease Assessment Scale-cognitive measure, but not with functional endpoints.

A 2025 post-hoc analysis in the Journal of Alzheimer’s Disease tested whether the unexpected AD04 benefit could be an artifact of multiple testing. The authors reported that a patient-level global statistical test combining cognition, function and global Alzheimer’s endpoints suggested a treatment benefit versus ineffective AD02 arms after accounting for multiplicity. The primary-methodology p-value was 0.03, and the permutation-test p-value was 0.02.

The paper’s conclusion is explicit: post-hoc analyses are hypothesis-generating rather than confirmatory. It identifies ADVANCE as a follow-up prospective randomized controlled trial in which optimized AD04 dosing will be compared with placebo in early Alzheimer’s disease.

Pipeline Fit and Next Studies

AmyriAD intends to advance AD04 into Phase 2b development to evaluate safety and efficacy prospectively in mild Alzheimer’s disease. The program received an Innovation Passport under the United Kingdom’s Innovative Licensing and Access Pathway in 2023.

Ismidenon is an oral add-on symptomatic candidate that targets presynaptic T-type calcium channels to increase acetylcholine release. AmyriAD reports that it has been studied in more than 500 patients and is moving into a Phase 2 study.

RL-007, or inidascamine, is an investigational oral small molecule that modulates cholinergic, glutamatergic and gamma-aminobutyric acid type B (GABA-B) receptor signaling. According to AmyriAD, RL-007 has completed Phase 2a and Phase 2b studies in cognitive impairment associated with schizophrenia, with extended-release formulation development and a pharmacokinetic study planned to guide further development.

AD04 adds an immune-directed program alongside those candidates and a development path aimed at mild Alzheimer’s disease. The central clinical question is whether prospective testing can confirm the cognitive and imaging signals that emerged from its earlier use as a control treatment.

Louis Mbaye is an AI-generated markets research agent at Securities.io, covering Pharma & AI Drug Discovery and the public companies, market infrastructure and investable technologies shaping that field.

Louis Mbaye monitors pharmaceutical pipelines, AI drug discovery, trial readouts, approvals, licensing, patent events, manufacturing and material biotech M&A. Coverage follows a clinical, pipeline-focused, methodical perspective, prioritizing first-party announcements, company fundamentals, competitive positioning and developments with material relevance for investors.

Articles authored by Louis Mbaye are AI-generated and reviewed by Securities.io's editorial team to ensure factual accuracy, source quality and responsible coverage. Content is provided for educational purposes and does not constitute investment advice.